Sandu Pharmaceuticals Limited has completed the mandatory newspaper publication of its unaudited standalone financial results for the third quarter of FY26 ended 31st December 2025, in compliance with SEBI (LODR) Regulations 2015. The company published its financial results in "Navprabha" and "Navhind Times" newspapers dated 7th February 2026, following board approval on 6th February 2026.

Regulatory Compliance and Publication

The company submitted newspaper cuttings to the Bombay Stock Exchange Limited through a formal communication dated 7th February 2026. Company Secretary Pratika Mhambray signed the compliance letter, confirming that the financial results were published as required under Regulation 30 of SEBI (LODR) 2015.

Q3FY26 Financial Performance

The published results demonstrate strong financial performance for Q3FY26, with net profit reaching ₹97.51 lakhs compared to ₹55.55 lakhs in Q3FY25. Revenue from operations stood at ₹1876.09 lakhs for Q3FY26, showing consistent operational performance.

Nine-Month Performance Summary

For the nine-month period ended 31st December 2025, the company reported total income of ₹5316.04 lakhs and net profit of ₹172.27 lakhs. Basic earnings per share for the nine-month period stood at ₹1.78 compared to ₹1.27 in the previous year.

Corporate Governance

The financial results were reviewed by the audit committee and approved by the board of directors. The company maintains compliance with Indian Accounting Standards (Ind AS) and SEBI regulations. Complete financial results are available on the company's website www.sandu.in and stock exchange websites.

Source: Newspaper Publication Documents

Sandu Pharmaceuticals Limited has filed its quarterly compliance statement with the Bombay Stock Exchange (BSE) confirming no deviation in the utilization of funds raised through preferential issue for the quarter ended December 31, 2025. The statement, submitted on February 6, 2026, covers three separate tranches of fund raising conducted between 2021 and 2022.

Fund Utilization Across Three Tranches

The company reported complete adherence to original fund utilization objectives across all three tranches of preferential issue. The comprehensive statement demonstrates systematic fund deployment for intended business purposes.

Original Fund Utilization Objectives

The proceeds from all three tranches were designated for specific business enhancement activities. The company allocated funds toward revamping existing capital machinery, developing marketing infrastructure, and civil work required for major plant and machinery. Additional objectives included:

• Purchase of new and additional plant and machinery
• Working capital requirements
• Investment in new technologies
• General business enhancement purposes

Regulatory Compliance and Oversight

The statement was prepared pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and SEBI Circular CIR/CFD/CMD1/162/2019 dated December 24, 2019. The Audit Committee reviewed the statement and noted approval of the fund utilization pattern across all tranches.

Outstanding Fund Balance

For the third tranche, the company maintains unutilized funds in an escrow account as of December 31, 2025. A fixed deposit has been created in the name of the company with Bank of Baroda to facilitate fund utilization as and when required for approved objectives.

The statement was signed by Pratika Mhambray, Company Secretary & Compliance Officer, and Umesh Sandu, Managing Director (DIN: 01132141), confirming the accuracy of the reported fund utilization status.